KAZIA THERAPEUTICS LTD (KZIA) Form 424B3 — Sep 1, 2026
Kazia Therapeutics filed a 424B3 prospectus supplement covering 232,956 ADSs (116,478,000 ordinary shares) under its F-1 (No. 333-290598), incorporating its September 1, 2026 Form 6-K, which contains two press releases on lead drug paxalisib. The ADSs last traded at $13.77 on Nasdaq on August 31, 2026. In colorectal cancer, preclinical data showed paxalisib monotherapy cut tumor burden by 52% (p=0.035) in immunotherapy-resistant MSS/pMMR models, and adding paxalisib to immunotherapy reduced tumor volume by an additional 50% versus immunotherapy alone (p=0.022), with no treatment-related toxicity.
Key figures
- Shares Offered
- 232,956 ADSs representing 116,478,000 ordinary shares (resale registration under F-1 No. 333-290598)
- Crc Full Enrollment
- end of 2027
- Paxalisib Doses Tested
- 15mg and 30mg
- Breast Full Data Readout
- 2028
- Crc Phase2 Enrollment Start
- Q1 2027
- Last Reported Ads With Price
- $13.77 per ADS (Nasdaq close, Aug 31, 2026)
- Breast Expansion First Patient
- by end of 2026
- Mss Pmmr Share Of Metastatic CRC
- 85-90%
- Breast Expansion Full Enrollment
- end of 2027
- Paxalisib Clinical Trials To Date
- over 15
- Expected New USHr Plus Her2 Neg Cases
- approximately 322,000 this year
- Tumor Burden Reduction Monotherapy CRC
- 52% (p=0.035)
- Hr Plus Her2 Neg Share Of Breast Cancer Diagnoses
- 60-70%
- Additional Tumor Volume Reduction Vs Immunotherapy Alone
- 50% (p=0.022)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.